Tags

Type your tag names separated by a space and hit enter

A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis.
Ther Deliv. 2015; 6(6):653-9.TD

Abstract

Rhinitis is a very common disease and represents a health problem for both children and adults globally. Rhinitis can be allergic or occur without any IgE-mediated sensitization to aeroallergens. Common symptoms include nasal congestion, postnasal drainage, nasal itching, rhinorrhea and sneezing. The most effective drugs for the treatment of rhinitis are antihistamines and topical glucocorticoids. MP29-02 (Dymista(®)) is a novel intranasal formulation combining the second-generation antihistamine, azelastine hydrochloride, with fluticasone propionate in a single device that has recently been developed. Here, we review the efficacy and safety profile of this intranasal formulation in the treatment of allergic and nonallergic rhinitis.

Authors+Show Affiliations

Department of Clinical & Experimental Medicine, University of Parma, Parma, Italy.Department of Clinical & Experimental Medicine, University of Parma, Parma, Italy.Department of Clinical & Experimental Medicine, University of Parma, Parma, Italy.Department of Clinical & Experimental Medicine, University of Parma, Parma, Italy.Pulmonary Rehabilitation Unit, ICP Hospital, Milan, Italy.Allergy & Respiratory Diseases Clinic, DIMI, University of Genoa, IRCCS AOU San Martino-IST, Genoa, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25913181

Citation

Ridolo, Erminia, et al. "A Role for the Intranasal Formulation of Azelastine Hydrochloride/fluticasone Propionate in the Treatment of Allergic Rhinitis." Therapeutic Delivery, vol. 6, no. 6, 2015, pp. 653-9.
Ridolo E, Montagni M, Melli V, et al. A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis. Ther Deliv. 2015;6(6):653-9.
Ridolo, E., Montagni, M., Melli, V., Bonzano, L., Incorvaia, C., & Canonica, G. W. (2015). A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis. Therapeutic Delivery, 6(6), 653-9. https://doi.org/10.4155/tde.15.7
Ridolo E, et al. A Role for the Intranasal Formulation of Azelastine Hydrochloride/fluticasone Propionate in the Treatment of Allergic Rhinitis. Ther Deliv. 2015;6(6):653-9. PubMed PMID: 25913181.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis. AU - Ridolo,Erminia, AU - Montagni,Marcello, AU - Melli,Valerie, AU - Bonzano,Laura, AU - Incorvaia,Cristoforo, AU - Canonica,Giorgio Walter, Y1 - 2015/04/27/ PY - 2015/4/28/entrez PY - 2015/4/29/pubmed PY - 2016/8/16/medline SP - 653 EP - 9 JF - Therapeutic delivery JO - Ther Deliv VL - 6 IS - 6 N2 - Rhinitis is a very common disease and represents a health problem for both children and adults globally. Rhinitis can be allergic or occur without any IgE-mediated sensitization to aeroallergens. Common symptoms include nasal congestion, postnasal drainage, nasal itching, rhinorrhea and sneezing. The most effective drugs for the treatment of rhinitis are antihistamines and topical glucocorticoids. MP29-02 (Dymista(®)) is a novel intranasal formulation combining the second-generation antihistamine, azelastine hydrochloride, with fluticasone propionate in a single device that has recently been developed. Here, we review the efficacy and safety profile of this intranasal formulation in the treatment of allergic and nonallergic rhinitis. SN - 2041-6008 UR - https://www.unboundmedicine.com/medline/citation/25913181/A_role_for_the_intranasal_formulation_of_azelastine_hydrochloride/fluticasone_propionate_in_the_treatment_of_allergic_rhinitis_ L2 - https://www.future-science.com/doi/full/10.4155/tde.15.7?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -